Abstract: OBJECTIVE To investigate the applied worth of rapid anticoagulation protocol in acute ischemic stroke with none valvular atrial fibrillation (NVAF) in China. METHODS Selected 101 patients with acute ischemic stroke and NVAF from January 2013 to February 2016. They were openly divided into rapid anticoagulation group and empirical anticoagulation group. The initial dose of warfarin was 3-4.5 mg in rapid anticoagulation group. Then the dose adjustment in everyday was followed by a novel protocol. The initial dose of warfarin was 1-3 mg in empirical group. Then the dose adjustment was followed by doctors assessment of patient's risk and benefit. RESULTS The rate of patients reaching a stable INR in rapid anticoagulation group was significantly higher than in empirical group in 1 week, 2 weeks and 1 month after began anticoagulation (48.2% vs 4.4%, P=0.000; 91.1% vs 40.0%, P=0.000; 96.4% vs 48.9%, P=0.000). Time to stable warfarin dosing in rapid group was shorter than empirical group(8.3±2.9)d vs (13.2±4.5)d, P=0.000. The rate of patients reaching a stable INR after one year in rapid anticoagulation group was also significantly higher than in empirical group(54.5% vs 31.8%, P<0.05). The rate of INR>4 at 2 weeks was 5.4%(3/56) in rapid anticoagulation group and 6.7%(3/45) in empirical group. CONCLUSION Rapid anticoagulation protocol is more effective and safe than empirical anticoagulation group. What is more, rapid anticoagulation protocol improves NVAF patients' compliance. So rapid anticoagulation protocol has an extensive application value in China.